Pancreaze (Pancrelipase) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The pancreaze (pancrelipase) market size has grown strongly in recent years. It will grow from $1.66 billion in 2025 to $1.75 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing incidence of pancreatic insufficiency, rising prevalence of cystic fibrosis, limited natural enzyme production therapies, advancements in pharmaceutical enzyme formulation, expansion of gastroenterology care services.

The pancreaze (pancrelipase) market size is expected to see strong growth in the next few years. It will grow to $2.17 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to expansion of long-term digestive disease management, increasing adoption of personalized enzyme dosing, growing elderly population with digestive disorders, rising awareness of pancreatic enzyme therapies, improvements in oral drug delivery technologies. Major trends in the forecast period include increasing demand for enzyme replacement therapies, rising focus on digestive disorder management, expansion of personalized dosage formulations, growing use of chronic enzyme supplementation, enhanced stability of oral enzyme products.

The rising incidence of cystic fibrosis is expected to drive the growth of the Pancreaze (pancrelipase) market in the coming years. Cystic fibrosis is a genetic disorder that impacts the lungs, digestive system, and other organs by causing the production of thick, sticky mucus. This leads to blockages, infections, and impaired organ function. The increase in cystic fibrosis cases is largely attributed to improved awareness, better diagnostic techniques, and expanded genetic screening programs that help identify more cases, including milder forms that may have previously gone undiagnosed. Pancreaze (pancrelipase) is used in the treatment of cystic fibrosis to assist digestion by replacing the enzymes that the pancreas cannot produce effectively. This helps patients absorb nutrients from food, improving their overall nutritional health. For example, in October 2024, the Cystic Fibrosis Trust, a UK-based charity, reported that in 2022, 11,148 cystic fibrosis patients were registered, with the number rising to 11,318 in 2023, reflecting a 1.5% increase in patient registrations year-over-year. As a result, the growing prevalence of cystic fibrosis is driving the growth of the Pancreaze (pancrelipase) market.

The increasing incidence of pancreatic conditions is expected to further drive the growth of the Pancreaze (pancrelipase) market. Pancreatic conditions, which include disorders such as pancreatitis, exocrine pancreatic insufficiency (EPI), pancreatic cancer, and diabetes, impair the pancreas' digestive and hormonal functions. The incidence of these conditions is on the rise due to factors such as obesity, diabetes, alcohol overuse, smoking-related complications, and improved diagnostic tools that enable earlier detection. Pancreaze helps manage these conditions by restoring digestive enzyme levels, improving nutrient absorption, and alleviating symptoms like malnutrition and diarrhea. For instance, in February 2023, Cancer Research UK, an independent cancer research organization, reported that the annual number of new pancreatic cancer cases in the UK is expected to rise from approximately 12,500 cases in 2023-2025 to around 16,000 cases by 2038-2040. This represents a 5% growth in incidence rates, reaching an average of 19 cases per 100,000 people annually by 2038-2040. Therefore, the increasing incidence of pancreatic conditions will drive the growth of the Pancreaze (pancrelipase) market.

A key trend in the Pancreaze (pancrelipase) market is the increasing emphasis on clinical evidence to support the drug's efficacy, particularly through clinical trial data. This data plays a crucial role in enhancing regulatory approval processes, improving patient outcomes, and strengthening a drug's competitive positioning. For example, in May 2024, Vivus, Inc., a US-based biopharmaceutical company, announced the publication of new clinical trial data highlighting the efficacy of PANCREAZE (pancrelipase) in stabilizing weight among chemotherapy patients with pancreatic ductal adenocarcinoma (PDAC) who were also suffering from cachexia and exocrine pancreatic insufficiency (EPI). The findings also suggested potential benefits of PANCREAZE in reducing stool frequency and improving stool consistency. This study was conducted as an investigator-initiated trial by researchers at Cedars-Sinai Medical Center and the Samuel Oschin Cancer Center.

Major companies operating in the pancreaze (pancrelipase) market are AbbVie Inc.

North America was the largest region in the pancreaze (pancrelipase) market in 2025. The regions covered in the pancreaze (pancrelipase) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pancreaze (pancrelipase) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the pancreaze market by increasing costs associated with imported active enzyme ingredients, pharmaceutical-grade excipients, capsule manufacturing materials, and specialized processing equipment. These impacts are most evident in North America and Europe, where enzyme-based drug production depends on global sourcing networks. Higher tariffs can increase production costs and affect pricing strategies for chronic therapies. However, they are also encouraging domestic enzyme production, regional sourcing of raw materials, and investments in localized pharmaceutical manufacturing capacity to strengthen supply reliability.

The pancreaze (pancrelipase) market research report is one of a series of new reports that provides pancreaze (pancrelipase) market statistics, including pancreaze (pancrelipase) industry global market size, regional shares, competitors with a pancreaze (pancrelipase) market share, detailed pancreaze (pancrelipase) market segments, market trends and opportunities, and any further data you may need to thrive in the pancreaze (pancrelipase) industry. This pancreaze (pancrelipase) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pancreaze (pancrelipase) is a prescription medication that combines digestive enzymes, including amylase, lipase, and protease, to help the body digest food. It is primarily prescribed to individuals with pancreatic insufficiency, which can be caused by conditions such as cystic fibrosis or chronic pancreatitis.

The main forms of Pancreaze (pancrelipase) are capsules and tablets. The capsule form is designed to be swallowed whole and contains a powder or granules inside a soft or hard shell that dissolves in the stomach, releasing the active enzymes. Pancreaze is used across various age groups, including children, adults, and geriatrics. It is distributed through several channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The medication is typically used to manage conditions like chronic pancreatitis, cystic fibrosis, and other related applications.

The pancreaze (pancrelipase) market consists of sales of pancreaze delayed-release capsules, pancreaze powder, and pancreaze oral pellets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.